A New Momentum for Renal Denervation: 2023 ESH Guidelines
Published: 12 December 2023
-
Views:
5157
-
Likes:
7
-
Views:
5157
-
Likes:
7
-
Up Next
-
13m 11sPart 4 How to Build the Therapy?
-
20m 15sPart 5 Q&A
-
7m 13sPart 1 ESH 2023 Guidelines – What’s new? Joost Daemen, Dagmara Hering
-
11m 4sPart 2 Ultrasound RDN Clinical Evidence Joost Daemen, Dagmara Hering
Overview
In light of the recent ESC clinical consensus statement on Renal Denervation (RDN), a significant development has occurred in the management of hypertension. The European Society of Hypertension (ESH) has officially endorsed Renal Denervation as a recommended treatment for hypertension. This marks a pivotal moment in the field of hypertension management.
This broadcast features a compelling discussion between two distinguished experts, Dr Joost Daemen (Erasmus University Medical Center, Rotterdam, NL) and Prof Dagmara Hering (Medical University of Gdańsk, Gdańsk, PL). They provide invaluable insights into how these new guidelines impact their approach to patient selection and the adjustments that should be made in the patient care pathway for hypertension treatment. Gain a deeper understanding of the evolving landscape of hypertension management in this engaging conversation.
Learning Objectives
- Learn about the 2023 ESH guidelines about Renal Denervation
- Deep dive into class of recommendation and level of evidence
- Overview of Ultrasound RDN clinical evidence
- Understand recommended patient pathways and hear case discussions.
Target Audience
- Interventional Cardiologist
- Hypertension Specialist
- General Physician
- Nephrologist
- Cardiologist
- Internal medicine
More from this programme
Part 1
ESH 2023 Guidelines – What’s new?
| 1 session | |
| ESH 2023 Guidelines – What’s new? | Watch now |
Part 2
Ultrasound RDN Clinical Evidence
| 1 session | |
| Ultrasound RDN Clinical Evidence | Watch now |
Part 3
Who to Treat With RDN?
| 1 session | |
| Who to Treat With RDN? | Watch now |
Part 4
How to Build the Therapy?
| 1 session | |
| How to Build the Therapy? | Watch now |
Faculty Biographies
Joost Daemen
Interventional Cardiologist
Dr Joost Daemen is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center. He is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.
Dagmara Hering
Professor
Prof Dagmara Hering is a medical scientist and clinical specialist in internal medicine, a specialist in hypertension, and a cardiologist at the Medical University of Gdansk, Gdansk, PL.
She is also a Professorial Fellow at Baker IDI Heart and Diabetes Institute, Melbourne, AU and a Clinical Expert of the European Society of Hypertension, and a Fellow of the European Society of Cardiology.
Her clinical research has been focused on the role of the sympathetic nervous system in hypertension, and cardiovascular and renal diseases, and has substantially contributed to the understanding of the efficacy of device-based therapies including renal denervation.
Comments